| INTRODUCTION
First described in 1983, gastrointestinal stromal tumors (GISTs) are the most common sarcoma of the gastrointestinal tract. [1] [2] [3] While the majority of these tumors are thought to arise spontaneously, approximately 5% are considered hereditary. 4 There are multiple single institution and population based studies that have shown GIST patients to have an increased risk of developing additional malignancies, including renal cell carcinoma. [5] [6] [7] [8] [9] Similar to GISTs, a minor proportion (5-8%) of RCCs are known to occur due to hereditary etiology, and some with an identifiable genetic abnormality. 10 Prior studies, based on smaller case series, and individual reports have identified specific genetic mutations in patients diagnosed with both RCC and GIST within a lifetime. [11] [12] [13] [14] [15] While these studies suggest an association between these two malignancies, limited conclusions can be drawn due to their small sample sizes of 1-3 patients. In an effort to elucidate a true association between RCC and GIST, we report our findings after retrospectively analyzing our 26-year experience of patients diagnosed and surgically treated for both RCC and GIST.
| METHODS AND MATERIALS
This study was conducted using two prospectively maintained oncology databases from the Sarcoma and Urology division within 
| Clinical and pathological variables and outcomes
The primary objective of this study was to describe the prevalence of RCC and GIST co-occurrence. In addition, we aimed to characterize a possible association between these malignancies by evaluating the temporal relationship between their diagnoses and identifying common clinical characteristics in these patients. Baseline demographic and clinicopathologic data, including age, gender, tumor characteristics, chronologic occurrence, and survival data, were captured. Data was presented as either continuous variables with a corresponding range or categorical variables. Chronologic co-occurrence of GIST and RCC was defined as either synchronous or metachronous. Synchronous cooccurrence was considered if a patient was diagnosed with GIST and RCC within a 6-month period. Metachronous co-occurrence was considered as RCC being diagnosed greater than 6 months after GIST.
| RESULTS
During the study period, the sarcoma database was searched, and we identified a total of 405 patients who were surgically treated for GISTs at MKSCC. Of these 405 patients, 9 (2.2%) also had a diagnosis of RCC, and were surgically treated at our institution. To validate our results, we independently queried the RCC database, between the same study time period, for patients who had a diagnosis of GIST, which resulted in the same nine patients. Pathologic characteristics specific to RCC are presented in Table 1 . The diagnosis of RCC was made at the same time as the diagnosis of GISTs in 5/9 (55.6%) patients, prior to GIST diagnosis in 2/9 (22.2%) and after in 2/9 (22.2%). Mean RCC tumor size at diagnosis was 3.0 cm (range 1.8-8.0). After surgical resection 8/9
(88.9%) patients were found to have stage pT1 RCC on pathologic examination. Histologically, RCC tumors had a high frequency of clear cell (n = 4/9, 44.4%) and papillary RCC (n = 4/9, 44.4%).
Baseline clinical characteristics for all patients and GIST tumor characteristics are displayed in Tables 2 and 3 At last follow-up, 6/9 (66.7%) patients were alive. Of those alive, 4/9 (44.4%) had no evidence of GIST recurrence and 2/9 (22.2%) had metastatic GIST. Two out of nine (22.2%) patients died from GIST and 1/9 (11.1%) died from other causes. None of the patients had evidence of RCC recurrence, metastases, or death at last follow up.
| DISCUSSION
Prior small case reports and series have looked at individual patients with co-occurring RCCs and GISTs to hypothesize an association between them. Some studies have shown synchronous GIST and RCC occurrence due to germline mutations in SDHA, SDHC, or a translocation of Xp11. [11] [12] [13] In addition, there are case reports and series that identify an association of GIST with papillary RCC over other RCC histologies. [14] [15] While these studies support RCC and GIST association, there is an absence of large population studies to validate, and assess a true relationship between these malignancies. To our knowledge, our study involves searching through the largest cohort of RCC, and GIST patients over a lengthy study timeframe of 26 years.
The association between RCC and GIST is supported by common genetic and molecular pathways involving tyrosine kinase, which results in the development of these malignancies. Specific to RCC, the majority of cases is dependent on mutations of the VHL gene. 16 Under ideal physiologic conditions, the products of VHL bind to transcriptional factor hypoxia-inducible factor (HIF-1α) rendering it inactive. 17 However when VHL is mutated, HIF-1α becomes perpetually active, and binds to a variety of cofactors that ultimately promotes uninhibited transcription of products including VEGFR, which leads to angiogenesis, and EGFR and PDGFR, which leads to cell growth. 
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Activating KIT and PDGFR-α mutations are dependent on tyrosinekinase mediated pathways that are essential for GIST development. GIST, further research is required to identify a specific genetic mutations, or a hereditary syndrome for these co-occurring malignancies. Prior studies have identified specific genetic mutations in individual case reports, however, no genetic testing has been performed in a larger series of co-occurring RCC, and GIST. [11] [12] [13] The patients in our series did not undergo genetic testing, however multiple unique clinical findings, aside from the co-occurrence of RCC and GIST, suggest the possibility of a familial syndrome. A majority of patients (55.6%) had other malignancies in addition to RCC and GIST. Furthermore, our results also identified a high occurrence of pRCC (44%) with GIST, which is consistent with findings in prior case reports. [14] [15] The frequency of pRCC in our data is additionally higher that the expected relative frequency (12-14%) in the overall RCC population. 26 pRCC can occur as a recurrent familial tumor involving mutations in the receptor tyrosine kinase molecule c-MET. 27 Finally, our results found a disproportionately higher frequency of GIST originating from the small bowel (44%), relative to the expected frequency in the overall population (31.8%).
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While further genetic testing and investigation is required to establish genetic mutations and familial syndromes, the increased frequency of additional malignancies, pRCC, and GISTs originating from the small bowel suggest its possibility.
Given the retrospective nature of the study, and the increased use of serial imaging on patients with GISTs during follow up, there is a potential bias for over-detecting RCC within the study population.
Once a patient is diagnosed and treated for GIST, serial imaging is an integral component of follow-up care to evaluate for tumor recurrence, or progression to metastatic disease. Evidence in our series Moreover, as the largest study investigating the concomitant occurrence of GIST and RCC, we feel that our findings support the association of RCC with GIST.
| CONCLUSIONS
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